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Available online 17 August 2016 Purpose: Breast cancer patients with high proportion of cancer stem cells (BCSCs) have unfavorable clinical out­
comes. MicroRNAs (miRNAs) regulate key features of BCSCs. We hypothesized that a biology-driven model based 
on BCSC-associated miRNAs could predict prognosis for the most common subtype, hormone receptor (HR)-pos­
itive, HER2-negative breast cancer patients. 
Patients and Methods: After screening candidate miRNAs based on literature review and a pilot study, we built a 
miRNA-based classiﬁer using LASSO Cox regression method in the training group (n = 202) and validated its 
prognostic accuracy in an internal (n = 101) and two external validation groups (n = 308).  
Results: In this multicenter study, a 10-miRNA classiﬁer incorporating miR-21, miR-30c, miR-181a, miR-181c, 
miR-125b, miR-7, miR-200a, miR-135b, miR-22 and miR-200c was developed to predict distant relapse free sur­
vival (DRFS). With this classiﬁer, HR+HER2− patients were scored and classiﬁed into high-risk and low-risk 
disease recurrence, which was signiﬁcantly associated with 5-year DRFS of the patients. Moreover, this classiﬁer 
outperformed traditional clinicopathological risk factors, IHC4 scoring and 21-gene Recurrence Score (RS). The 
patients with high-risk recurrence determined by this classiﬁer beneﬁt more from chemotherapy. 
Conclusions: Our 10-miRNA-based classiﬁer provides a reliable prognostic model for disease recurrence in 
HR+HER2− breast cancer patients. This model may facilitate personalized therapy-decision making for 
HR+HER2− individuals. 
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200 C. Gong et al. / EBioMedicine 11 (2016) 199–209 1. Introduction Hormone receptor (HR)-positive, HER2-negative breast cancer ac­
counts for approximately 60% of all primary breast cancer cases (Sorlie 
et al., 2003), and around 20% of early-stage estrogen receptor (ER)-posi­
tive patients may develop local or distant recurrences after treatment. 
HR-positive, HER2-negative breast cancer patients usually have a lower 
risk of tumor recurrence, and thus some of them cannot beneﬁt from cy­
totoxic chemotherapies (Ring et al., 2004) leading to overtreatment of the 
patients. Therefore, a prognostic and predictive model for HR-positive, 
HER2-negative breast cancer is needed in clinical practice. To meet this 
end, gene assays, such as Oncotype Dx and PAM50, have been developed 
and validated in multiple clinical trial. However, these models employed 
computer-based algorithms to select candidate genes for investigation 
without considering their biological rationales. A hypothesis-driven ap­
proach involving factors in DNA repair pathways has been used in a scor­
ing system for ovarian cancer patients treated with platinum-based 
chemotherapies, which effectively predicted their clinical outcomes 
(Kang et al., 2012; Paik et al., 2004). Thus, selecting target genes for Total Patients enrolled from
(n
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Fig. 1. Consort diagram for the availability of samples for analysis. SYSMH = Sun Yat-sen Me
epidermal growth factor receptor 2; and IHC = immunohistochemistry. molecular signatures of prognosis and therapeutic prediction by weighing 
their biological rationales emerges as an effective and economic approach. 
Cancer stem cells (CSCs) are a subpopulation of tumor cells with stem 
cell like features in solid malignancies, which play an important role in 
cancer recurrence and metastasis. Breast cancer patients with an elevated 
proportion of cancer stem cells identiﬁed by immunostaining for markers 
of breast cancer stem cell (BCSC), including ALDH1 and CD44highCD24low, 
reveal unfavorable clinical outcome and poor survival(Dai et al., 2012; 
Ginestier et al., 2007; Gong et al., 2010). However, the lack of speciﬁcity 
and limited number of BCSC markers restrict their application as effective 
biomarkers in clinical practice. Moreover, most of these markers do not 
actually reﬂect the functional features of BCSCs. On the other hand, our 
previous study demonstrated that BCSCs express a unique proﬁle of 
microRNAs (miRNAs), and the deregulated miRNAs play a crucial role 
in governing BCSC biology (Dalerba and Clarke, 2013; Dirks, 2009). 
These BCSC-associated miRNAs may function as oncogenes or tumor sup­
pressor genes to regulate self-renewal, anti-apoptosis, invasiveness, 
transdifferentiation into vascular endothelial cells and chemotherapeutic 
resistance of BCSCs, and thus contribute to progression and recurrence of  SYSMH between 2001 and 2010 
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Table 1 
Clinical characteristics of patients according to the 10-miRNA classiﬁer in the training, internal and two external validation groups. 
Training groupa Internal validation groupa External validation group-1b External validation group-2c 
Low risk High risk P Low risk High risk P Low risk High risk P Low risk High risk P 
Variables Total (%) (%) value Total (%) (%) value Total (%) (%) value Total (%) (%) value 
Age ≤40 years 17 12 (70.6%) 5 (29.4%) 0.299 16 10 (62.5%) 6 (37.5%) 0.003 26 18 (69.2%) 8 (30.8%) 0.571 27 24 (88.9%) 3 (11.1%) 0.139 
N40 years 185 150 (81.1%) 35 (18.9%) 85 77 (90.6%) 8 (9.4%) 126 94 (74.6%) 32 (25.4%) 129 98 (76.0%) 31 (24.0%) 
Menopause Yes 127 98 (77.2%) 29(22.8%) 0.201 62 53 (85.5%) 9(14.5%) 0.81 83 54(65.1%) 29(34.9%) 0.01 101 81(80.2%) 20(19.8%) 0.424 
No 75 64 (85.3%) 11(14.7%) 39 34 (87.2%) 5(12.8%) 69 58(84.1%) 11(15.9%) 55 41(74.5%) 14(25.5%) 
Tumor size ≤2 cm 72 61 (84.7%) 11 (15.3%) 0.23 35 34 (97.1%) 1 (2.9%) 0.02 33 26 (78.8%) 7 (21.2%) 0.452 39 34 (87.2%) 5 (12.8%) 0.117 
N2 cm 130 101 (77.7%) 29 (22.3%) 66 53 (80.3%) 13 (19.7%) 119 86 (72.3%) 33 (27.7%) 117 88 (75.2%) 29 (24.8%) 
Lymph node Negative 97 88 (90.7%) 9 (9.3%) b0.0001 57 57 (100%) 0 (0.0%) b0.0001 85 71 (83.5%) 14 (16.5%) 0.002 46 41 (89.1%) 5 (10.9%) 0.033 
Positive 105 74 (70.5%) 31 (29.5%) 44 30 (68.2%) 14 (31.8%) 67 41 (61.2%) 26 (38.8%) 110 81 (73.6%) 29 (26.4%) 
TNM stage I 45 43 (95.6%) 2 (4.4%) b0.0001 26 26 (100%) 0 (0.0%) b0.0001 22 20 (90.9%) 2 (9.1%) 0.05 35 29 (82.9%) 6 (17.1%) 0.006 
II 100 87 (87.0%) 13 (13.0%) 53 52 (98.1%) 1 (1.9%) 90 67 (74.4%) 23 (25.6%) 69 60 (87.0%) 9 (13.0%) 
III 57 32 (56.1%) 25 (43.9%) 22 9 (40.9%) 13 (59.1%) 40 25 (62.5%) 15 (37.5%) 52 33 (63.5%) 19 (36.5%) 
Tumor grade I 25 23 (92.0%) 2 (8.0%) 0.114 16 16 (100%) 0 (0.0%) 0.08 13 9 (69.2%) 4 (30.8%) 0.703 10 9 (90.0%) 1 (10.0%) 0.35 
II-III 177 139 (78.5%) 38 (21.5%) 85 71 (83.5%) 14 (16.5%) 139 103 (74.1%) 36 (25.9%) 146 113 (77.4%) 33 (22.6%) 
PR Negative 75 63(84.0%) 12(16.0%) 0.362 43 36(83.7%) 7(16.3%) 0.572 59 41(69.5%) 18(30.5%) 0.45 59 46(78.0%) 13(22.0%) 0.955 
Positive 127 99(78.0%) 28(22.0%) 58 51(87.9%) 7(12.1%) 93 71(76.3%) 22(23.7%) 97 76(78.4%) 21(21.6%) 
Ki67 ≤14% 74 63 (85.1%) 11 (14.9%) 0.181 40 38 (95%) 2 (5.0%) 0.037 84 67 (79.8%) 17 (20.2%) 0.059 73 63 (86.3%) 10 (13.7%) 0.022 
N14% 128 99 (77.3%) 29 (22.7%) 61 49 (80.3%) 12 (19.7%) 68 45 (66.2%) 23 (33.8%) 83 59 (71.1%) 24 (28.9%) 
Surgery Mastectomy 112 89 (79.5%) 23 (20.5%) 0.77 60 49 (81.7%) 11 (18.3%) 0.116 142 106 (74.6%) 36 (25.4%) 0.309 147 114 (77.6%) 33 (22.4%) 0.508 
BCS 90 73 (81.1%) 17 (18.9%) 41 38 (92.7%) 3 (7.3%) 10 6 (60.0%) 4 (40%) 8 7 (87.5%) 1 (12.5%) 
Chemotherapy No 43 32 (74.4%) 11 (25.6%) 0.284 17 13 (76.5%) 4 (23.5%) 0.206 44 30 (68.2%) 14 (31.8%) 0.325 38 29 (76.3%) 9 (23.7%) 0.746 
Yes 159 130 (81.8%) 29 (18.2%) 84 74 (88.1%) 10 (11.9%) 108 82 (75.9%) 26 (24.1%) 118 93 (78.8%) 25 (21.2%) 
ET TAM 101 79(78.2%) 22(21.8%) 0.775 65 54(83.1%) 11(16.9%) 0.396 81 63(77.8%) 18(22.2%) 0.214 87 67(77.0%) 20(23.0%) 0.764 
AI 89 73(82.0%) 16(18.0%) 30 28(93.3%) 2(6.7%) 63 42(66.7%) 21(33.3%) 58 47(81.0%) 11(19.0%) 
TAM → AI 12 10(83.3%) 2(16.7%) 6 5(83.3%) 1(16.7%) 8 7(87.5%) 1(12.5%) 11 8(72.7%) 3(27.3%) 
IHC4 score Low risk 36 31 (86.1%) 5 (13.9%) 0.367 25 23 (92.0%) 2 (8%) 0.358 53 45 (84.9%) 8 (15.1%) 0.015 43 38 (88.4%) 5 (11.6%) 0.124 
Median risk 127 98 (77.2%) 29 (22.8%) 59 51 (86.4%) 8 (13.6%) 49 37 (75.5%) 12 (24.5%) 61 47 (77.0%) 14 (23.0%) 
High risk 39 33 (84.6%) 6 (15.4%) 17 13 (76.5%) 4 (23.5%) 50 30 (60.0%) 20 (40.0%) 52 37 (71.2%) 15 (28.8%) 
Total 202 162 (80.2%) 40 (19.8%) 101 87 (86.1%) 14 (13.9%) 152 112 (73.7%) 40 (26.3%) 156 122 (78.2%) 34 (21.8%) 
Data are mean (SD) or n (%), unless otherwise stated; P value is calculated by χ2 test or Fisher's exact test; a: Cohort 1 includes training group and internal validation group; b: external validation group-1 = Cohort 2; c: external validation group-2 = 
Cohort 3; PR: progesterone receptor; BCS: breast conserving surgery; ET: endocrine therapy; TAM → AI: tamoxifen followed by aromatase inhibitor. 
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202 C. Gong et al. / EBioMedicine 11 (2016) 199–209 the tumor. Indeed, an aberrant expression of BCSC-associated miRNAs 
has been related to patient prognosis and therapeutic (Arigoni et 
al., 2013; Yu et al., 2007). Therefore, studying the expression proﬁl­
ing of BCSC-associated miRNAs may provide a hypothesis-driven ap­
proach to construct a molecular signature with clear functional 
rationale to  predict  the prognosis and therapeutic beneﬁt of breast  
cancer patients. 
In the present study, we developed a 10 BCSC-associated miRNA­
based classiﬁer, to divide the HR-positive, HER2-negative breast cancer 
patients into high- and low-risk groups. We performed a multi-institu­
tional study to both internally and externally validate this classiﬁer as 
prognostic biomarkers of distant relapse-free survival (DRFS) for 
HR+HER− patients. Additionally, its prognostic efﬁcacy was further 
compared with each single miRNA, clinicopathological risk factors and 
IHC4 scoring. 
2. Patients and Methods 
2.1. Patients and Clinical Database 
We reviewed the 1568 breast cancer patients who were admitted in 
Sun Yat-sen Memorial Hospital (SYSMH) between June 1, 2000 and May 
31, 2010, and enrolled 343 eligible patients according to the inclusion 
and exclusion criteria in this study. Please refer to the Supplementary 
material for the details of eligibility criteria. Sample availability is shown 
in the consort diagram in Fig. 1. In addition to 40 patients for pilot 
study, the remaining 303 eligible samples (Cohort 1) are randomly divid­
ed into two groups for the model training (n = 202) and internal valida­
tion (n = 101), stratiﬁed by the distant recurrence events. The patients 
who enrolled in the Cancer Center of Sun Yat-sen University (Cohort 2, 
n = 152) and the Third Hospital of Nanchang City (Cohort 3, n = 156) 
during the same period are selected to match the clinicopathological 
characteristics of Cohort 1, and used for external validation. Among 
all the HR-positive, lymph node-negative breast cancer patients en­
rolled in this study, 21-gene assay (Surexam®, Guangzhou, China) 
(Paik et al., 2004; Zhang et al., 2015) was performed in 153 cases to 
generate a 21-gene Recurrence Score (21-gene RS) in the parafﬁn-
embedded tumor tissue samples and the results were compared 
with those generated with our 10 BCSC-associated miRNA classiﬁer. 
This was a retrospective study with de-identiﬁed information for all 
participants. Therefore, inform consents from patients were not 
needed and the institutional review board (IRB) reviews were 
waived based on the institutional policy. 
2.2. Identiﬁcation of BCSC-associated miRNAs 
A total of 35 miRNAs were identiﬁed BCSC associated and constantly 
detectable for the further study. The detailed identiﬁcation procedure of 
BCSC-associated miRNAs was referred in Fig. S1 and Supplementary 
materials. 
2.3. Construction of a BCSC-associated miRNA classiﬁer 
qRT-PCR was used to examine the expression level of 35 BCSC-as­
sociated miRNAs according to a standard protocol as described in the 
Supplementary Method Section. LASSO (Least Absolute Shrinkage 
and Selection Operator) Cox regression method (Simon et al., 
2011) was employed to construct a BCSC-associated miRNA classiﬁer 
for clinical prognosis. The detailed methods were described in the Fig. 2. Construction of the ten-miRNA-based classiﬁer. Risk score by the 10 miRNA-based class
training group (n = 202) (a), internal testing group (n = 101) (b), independent validation gr
hazard ratio (95% CI). ROC = receiver operator characteristic. AUC = area under the curve.
patients were classiﬁed as high- and low- risk subgroups. We used AUCs at 3 and 5 years to asSupplementary Method Section. We divided the patients into high-
and low-risk groups by K-means (Hartigan and Wong, 1979), and 
validated the sensitivity and speciﬁcity of this classiﬁer in predicting 
DRFS in all groups. Furthermore, we compared the prognostic value 
of the classiﬁer with IHC4 scoring and 21-gene RS, and investigated 
the association between chemotherapy and risk scores deﬁned by 
this classiﬁer. 
2.4. Statistical Analysis 
Clinical follow-up data was recorded by retrospective case-
note review with data from surviving patients censored every 
3 months or from telephone counseling every month. Outcome 
measures were distant relapse free survival (DRFS) deﬁned as 
the time from the  date  of  surgery  to  the  time  of  the  ﬁrst distant re­
lapse or the date of the last follow-up visit for patients (Gourgou-
Bourgade et al., 2015). t-test and the χ2 test were used to compare 
continuous and categorical variables of two groups. The Cox re­
gression model was performed for multivariate survival analysis. 
We used Kaplan-Meier method to display the survival curves and 
log-rank test to compare the difference between high- and low-
risk groups in survival. The receiver operating characteristic 
(ROC) curves were employed to test the sensitivity and speciﬁcity 
of variables in predicting DRFS. All statistical analyses were per­
formed at Sun Yat-sen Memorial Hospital, Sun Yat-sen University 
(Supervised by E.S.) and blind to group assignment and outcome 
assessment. 
3. Results 
3.1. Baseline Clinicopathological Status 
The baseline clinicopathological  features  and treatments of  three  
cohorts were comparable (Table 1). All the 611 patients received 
surgical resection and adjuvant endocrine therapy after surgery, 
and 469 (76.8%) of them received adjuvant chemotherapy with 
anthracycline or paclitaxel-based regiments or both, 334 (54.7%) of 
them received upfront tamoxifen, 240 (39.3%) of them received up-
front aromatase inhibitor (AI), 37 (6.0%) of them received tamoxifen 
followed by AI. There were 33.0% (123 out of 373) postmenopausal 
patients received upfront tamoxifen. The median follow-up was 
69.4 months, ranging from 8.1 to 120.4 months, and 130/611 
(21.3%) patients developed distant recurrence during the follow-up 
period. The 5-year and 7-year DRFS were 81.5% and 78.9% in Cohort 
1, 74.3% and 73.0% in Cohort 2, and 84.6% and 83.3% in Cohort 3, 
respectively. 
3.2. Construction of the 10 BCSC-associated miRNA-Based Prognostic Model 
We screened 35 BCSC-associated miRNAs as candidates based on lit­
erature review and a pilot assay (Fig. S1). The Kaplan-Meier analysis 
with Log-rank test suggested that 13 out of the 35 BCSC-associated 
miRNAs were associated with DRFS in these training and internal vali­
dation groups (Table S1). We used LASSO Cox regression method and 
identiﬁed 10 miRNAs with the highest frequency of being selected by 
this method among 200 bootstrap replicates, which were as follow: 
miR-30c, miR-21, miR-181a, miR-181c, miR-125b, miR-7, miR-200a, 
miR-135b, miR-22 and miR-200c. These 10 miRNAs were incorporated 
into a Cox proportional hazards regression model and the coefﬁcients iﬁer (left), time-dependent ROC curves (middle) and Kaplan-Meier survival (right) in the 
oup-1 (n = 152) (c) and independent validation group-2(n = 158) (d). Data are AUC or 
 We used K-means to generate the optimum cutoff score for the prognostic model and 
sess prognostic accuracy, and calculated p values using the log-rank test. 
203 C. Gong et al. / EBioMedicine 11 (2016) 199–209 
a. Training group 
1001.0
-6 
4 802 P<0.0001 0.80 HR 15.85(8.15-30.82) 
-2 
-4 600.6 
AUC at 3 years: 0.868 
AUC at 5 years: 0.897 
200.2
Fo
llo
w
-
u
p 
tim
e
 
R
is
k 
sc
o
re
 
D
R
FS
(%
) 
Se
n
sit
iv
ity
 
-6 
140 
80 
60 
40 
100 
120 
20 
Relapse Disease-free 
0 50 100 150 
400.4 
Low risk 
High risk 00 
0 0.2 0.4 0.6 0.8 1.0 0 20 40 60 80 100 1200 
1-specificity Follow-up time (months) 
NO. of patients NO. at risk 
High risk 40 38 17 10 3 0 0 
Low risk 162 158 134 111 47 9 0b. Internal validation group 
1001.04 
2 80 P<0.0001 0.8 
0.4 
AUC at 3 years: 0.798 
AUC at 5 years: 0.806 
Relapse Disease-free 
Fo
llo
w
-u
p 
tim
e
 
R
is
k 
sc
o
re
 
HR 20.622(8.305-51.201) 0 
-2 
D
R
FS
 
(%
) 
60 
40 
Se
ns
iti
vit
y 
Se
ns
iti
vit
y 
0.6
-4 
140 
120 
100 
80 20 Low risk 0.2 
60 High risk 040 020 0 20 40 60 80 100 1200 0.2 0.4 0.6 0.8 1.00 Follow-up time (months) 
0 20 40 60 80 100 1-specificity NO. at risk NO. of patients High risk 14 12 5 1 0 0 0 
Low risk  87  86 70 63 31  7  0  c. External validation group-1 
Relapse Disease-free 
Fo
llo
w
-
u
p 
tim
e
 
R
is
k 
sc
o
re
 
10 1001.0 
5
 
0
 800.8 P<0.0001 
0.4 
AUC at 3 years: 0.782 
AUC at 5 years: 0.788 
0 0.2 0.4 0.6 0.8 1.0 
-5 HR 6.623(3.54-12.39) 
D
R
FS
 
(%
) 
-10 
140 
120 
100 
80 
0.6 60 
40 
60 0.2 20 Low risk 40 
20 High risk 000 0 20 40 60 80 100 120 
0 50 100 150 1-specificity Follow-up time (months) NO. of patients NO. at risk 
High risk  40 33  26 15  13  8  0  
d. External validation group-2 Low risk 112 110 104 96 60 25 1 
-6 1001.04
 
2
 
0
 80 P<0.0001 0.8 
Relapse Disease-free 
Fo
llo
w-
u
p 
tim
e
 
R
is
k 
sc
o
re
 
0.4 
0.2 
AUC at 3 years: 0.707 
AUC at 5 years: 0.774 
0 0.2 0.4 0.6 0.8 1.0 
-2 
-4 
-6 
140 
120 
100 
80 
60 
40 
D
R
FS
 
(%
) HR 6.99(3.124-15.64) 
Se
n
si
tiv
ity
 
0.6 60 
40 
20 Low risk 
High risk 20 0 0 
0 0 20 40 60 80 100 1200 50 100 150 1-specificity Follow-up time (months) NO. of patients NO. at risk 
High risk 38  27  19 10 4  1  0  
Low risk 118 111 100 89 52 12 0 
204 C. Gong et al. / EBioMedicine 11 (2016) 199–209 were estimated using the data of patients from the training group. The 
risk score which were used to predict disease recurrence was given as 
follows, 
Risk score ¼ ð0:165 x expression ImiR−21Þ 
− ð0:812 x expression ImiR−30cÞ 
þ ð1:053 x expression ImiR−181a Þ 
þ ð0:179 x expression ImiR−181c Þ 
þ ð0:672 x expression ImiR−125b Þ 
− ð0:588 x expression ImiR−7Þ 
− ð0:469 x expression ImiR−200a Þ 
þ ð1:065 x expression ImiR−135b Þ 
− ð0:986 x expression ImiR−22Þ 
− ð0:820 x expression ImiR−200c Þ: 
In this formula, expression_ImiR-i indicates the log10-scaled expres­
sion value of miRNA-i. 
Patients were divided into high- and low-risk groups with the opti­
mal cut-off of risk scores (1.324) (Fig. 2 left panel). As shown in Table 1, 
the traditional clinicopathological status (e.g. LN status and TNM-stage) 
was associated with the predictive risk scores. 
In the training group, a time-dependent ROC analysis demonstrated 
that the AUC (Area under curve) for 3-year and 5-year DRFS of this clas­
siﬁer were 0.868 and 0.897(Fig.2a middle panel), respectively. Patients 
in the high-risk subgroup had a signiﬁcantly lower 5-year DRFS than 
those in the low-risk subgroup (28.3% vs. 92.1%, HR = 15.85, 95% CI 
8.15–30.82; p b 0.0001) (Fig. 2a right panel). 
3.3. Internal and External Validation 
In the internal validation group, patients deﬁned as high-risk by the 
classiﬁer had signiﬁcantly lower 5-year DRFS than the low-risk patients 
(7.1% vs. 89.7%, HR 20.62, 95% CI 8.31–51.20; p b 0.0001; Fig. 2b). In Co­
hort 2, 40 (26.3%) and 112 (73.7%) of the patients were classiﬁed into 
the high- and low-risk subgroups, respectively, and the 5-year DRFS in 
the high-risk subgroup was signiﬁcantly lower than that of the low-
risk one (37.5% vs. 87.5%, HR 6.62, 95% CI 3.54–12.39; p b 0.0001; Fig. 
2c). Similarly, in Cohort 3, the 5-year DRFS were 46.1% and 91.5% in 
the high-risk (n = 34, 21.8%) and the low-risk (n = 122, 78.2%) sub­
group, respectively (HR 6.99, 95% CI 3.12–15.64; p b 0.0001; Fig. 2d). 
3.4. Multivariate Analysis and Stratiﬁcation Analysis 
The prognostic risk score were signiﬁcantly associated with the clas­
sical prognostic factors, including menopausal status, tumor size, lymph 
node status, TNM, grade and ki67 (Fig. S2). After adjustment with the 
individual clinicopathological features, the prognostic risk score was 
still signiﬁcantly associated with the 5-year DRFS (Table 2 and S2). 
Stratiﬁcation analysis showed that our miRNA signature is superior in 
predicting DRFS of HR+HER2− breast cancer patients, independent 
of clinic pathological features including TNM staging, tumor size, LN Table 2 
Multivariate association of the 10-miRNA classiﬁer, clinicopathological characteristics with DR
Cohort 1 (n = 303) 
Variable HR (95% CI) P value 
10-miRNA classiﬁer (High vs. Low risk) 11.04(6.26–19.49) b0.0001 
Age (N40 years vs. ≤40 years) 0.86(0.44–1.65) 0.642 
Menopause(Yes vs. No) 0.85(0.46–1.56) 0.588 
T stage ( ≤2 cm  vs. N2 cm) 1.80(0.82–3.99) 0.145 
LN (positive vs. negative) 2.14(1.02–4.48) 0.044 
TNM stage ( III–II vs. I) 1.93(0.35–10.75) 0.452 
Grade ( III–II vs. I) 2.18(0.50–9.55) 0.303 
Ki67(N14% vs. ≤14%) 1.62(0.85–3.10) 0.143 
Chemotherapy (yes vs. no) 0.56(0.32–0.98) 0.042 
DRFS = disease relapse free survival; and LN = lymph node. status and histological grade (Fig. 3). In addition, the prognostic risk 
score was constantly accurate when the analysis was stratiﬁed by differ­
ent regiments of endocrine therapies including Tamoxifen upfront and 
AI upfront, ki67 expression, PR status and menopausal status (Fig. S3). 
3.5. Comparison with Other Prognostic Factors 
The prognostic accuracy of the 10 BCSC-associated miRNAs based 
classiﬁer for the DRFS was much better than any of the single BCSC-as­
sociated miRNA (Fig. 4a). Additionally, the classiﬁer was also signiﬁ­
cantly more accurate than any other single clinicopathological risk 
factor evaluated in our study (Fig. 4b). Speciﬁcity, we compared the 
AUC between the miRNA panel and TNM stage, and found that there 
was statistically signiﬁcant difference between these two variables 
(P = 0.0366), which was consistent with the stratiﬁcation analysis 
shown in Fig. 3. 
We quantiﬁed the IHC4 score for each patient and stratiﬁed the pa­
tients into low-, intermediate- or high- risk group (Fig. S4).·We ob­
served much closer association between the miRNA risk scoring with 
DRFS of theHR+HER2− breast cancer patients than the IHC4 risk scor­
ing ( miRNA RS high vs. low, HR 10.313, 95% CI 7.182–14.809; 
p b 0·0001; IHC4 RS high vs. low, HR 1.454, 95% CI 1.133–1.866; p = 
0.003; IHC4 RS high vs. intermediate, HR 1.370, 95% CI 0.931–2.061; 
p = 0.11; IHC4 RS intermediate vs. low, HR 1.508, 95% CI 0.941–2.418; 
p =0.088;  Fig. 5a). In patients with intermediate-risk scores as deﬁned 
by IHC4 scoring, our classiﬁer could further distinguish a high-risk sub­
group of patients with signiﬁcantly lower 5-year DRFS (Fig. 5b). This 
classiﬁer had better prognostic accuracy than IHC4 score in 611 
HR+HER2− patients (AUC 0·772 vs AUC 0.692) (Fig. 4b), probably 
due to the exclusion of HER2 positive patients. In addition, compared 
to IHC4 score, stratiﬁcation analysis showed that the miRNA RS was su­
perior in predicting DRFS of HR+HER2− breast cancer patients with 
high tumor burden including advanced TNM staging, larger tumor 
size, higher histological grade, lymph nodes metastasis and higher pro­
liferation index as well as in the patient subgroup aged over 40 (Fig. 
S5)·Therefore, these data suggest that the 10 BCSC-associated miRNAs 
based prognostic scoring may serve as a better prognostic model than 
IHC4 scoring in the HR+HER2 − subtype of Asian breast cancer 
patients. 
3.6. Comparison with 21-Gene Recurrence Score 
Since the 21-gene RS was validated to predict distant recurrence in 
patients with node-negative, estrogen-receptor-positive breast cancer 
(Paik et al., 2004), we selected node-negative patients from our cohort 
for the comparison between the miRNA and 21 gene RS. In our entire co­
hort, there were 33.0% (285 out of 611) patients with negative lymph 
node. Among the 285 patients without lymph node metastasis, we per­
formed 21-gene assay in 153 cases with qualiﬁed FFPE samples for the 
assay and generated a 21-gene recurrence score (21-gene RS) for each 
individual. The median follow-up period of this cohort was 70.7 (8.1– FS. 
Cohort 2 (n = 152) Cohort 3 (n = 156) 
HR (95% CI) P value HR (95% CI) P value 
4.95(2.51–9.74) b0.0001 5.65(2.38–13.42) b0.0001 
1.04(0.47–2.28) 0.926 0.65(0.20–2.13) 0.474 
0.76(0.37–1.56) 0.455 0.41(0.16–1.04) 0.061 
2.29(0.74–7.06) 0.15 1.37(0.07–26.02) 0.836 
1.96(0.98–3.91) 0.058 1.51(0.22–10.51) 0.678 
2.82(0.34–23.19) 0.336 2.65(0.11–63.06) 0.546 
3.06(0.70–13.43) 0.139 1.10(0.45–9.02) 0.927 
1.09(0.56–2.13) 0.801 2.90(1.04–8.09) 0.042 
0.52(0.26–1.02) 0.058 0.44(0.19–1.06) 0.068 
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Fig. 3. Kaplan-Meier survival analysis for 611 HR+HER2− patients according to the 10 miRNA-based classiﬁer stratiﬁed by clinical risk factors. (a–c) TNM stage (d–e) Tumor size. (f–g) 
Lymph node (LN) status. (h–i) Grade. 118.8) months. These LN negative cases (n = 153) were enrolled in 
three independent centers, with 85 cases from SYSMH, 43 cases from 
Cancer Center of Sun Yat-sen University, and 25 cases form the Third 
Hospital of Nanchang City. The baseline clinicopathological features of 
the 153 patients were comparable with the total 285 cases of LN-nega­
tive patients (Table S4). A direct comparison of the prognostic value be­
tween 10-miRNA classiﬁer and 21-gene RS was further performed in 
this cohort. As shown in Fig. 5c, the miRNA RS demonstrated a much 
closer association with the DRFS of HR+HER2− breast cancer patients 
than the 21-gene RS (miRNA RS high vs. low, HR 9.748, 95% CI 3.415– 
27.842, p b 0.0001; 21-gene RS high vs. low, HR 2.181, 95% CI 1.109– 
4.291, p = 0.004; 21-gene RS high vs. intermediate, HR 1.894, 95% CI 
0.554–6.474, p = 0.108; 21-gene RS intermediate vs. low, HR 1.012, 
95% CI 0.674–1.520, p = 0.953; Fig. 5c). Additionally, among the 40 patients with intermediate 21-gene RS, the 10 BCSC-associated 
miRNA classiﬁer could further identify a high-risk subgroup of pa­
tients with signiﬁcantly lower 5-year DRFS (miRNA RS high vs. 
low HR 6.59, 95% CI 2.20–19.70, P = 0.001, HR 12.55, 95% CI 
1.720–91.544, P = 0.013,  Fig. 5d). More importantly, the 10 BCSC-
associated miRNA classiﬁer showed a trend of better prognostic ac­
curacy than the 21-gene RS in the 153 HR+HER2 − patients tested, 
although it did not reach statistical difference (AUC 0.710 vs. 0.685, 
P =0.36)  (Fig. 5e). Stratiﬁcation analysis showed that the prognos­
tic accuracy  between  miRNA  RS  and  21-gene RS is comparable (Fig.  
S6), probably due to limited population in each subgroup. There­
fore, the 10 miRNAs-based classiﬁer seems to outperform the 21­
gene RS in predicting the DRFS for HR + HER2 − breast cancer 
patients. 
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Comparisons of the prognostic accuracy by the 10 miRNA-based classiﬁer (high vs. low risk), and any single BCSC-associated miRNA in the prediction of DRFS. miR-7 (high vs. low 
expression), miR-181c (high vs. low expression), miR-125b (high vs. low expression), miR-200a (high vs. low expression), miR-30c (low vs. high expression), miR-200c (low vs. high 
expression), miR-22 (low vs. high expression), miR-135b (low vs. high expression), miR-181a (low vs. high expression) and miR-21 (low vs. high expression). (b) Comparisons of 
prognostic accuracy by the 10 miRNA-based classiﬁer (high risk vs. low risk), TNM stage (II-III vs. I), tumor size (N2 cm  vs. ≤ 2 cm),pathological grade (II–III vs. I), lymph node (positive 
vs. negative), IHC4 score (high vs. low-intermediate risk), age (≤40 vs. N40), menopause (yes vs. no), Ki67 (≥14% vs. b14%). AUC = area under curve. ROC = receiver operator characteristic. 3.7. Association with Chemotherapy and Clinical Outcome 
In the validation population (n = 409), adjuvant chemotherapy 
was associated with a slight increase in 5-year DRFS (83.2% with 
chemotherapy vs. 66.7% without chemotherapy; HR 1.723, 95% CI 
1.117–2.658; P = 0.014; Fig. 6a). We observed a 30.7% improve­
ment of 5-year DRFS by chemotherapy in the high-risk subgroup 
(HR 1.765, 95% CI 1.024–3.043; P =0.041;  Fig. 6c), whereas chemo­
therapy was not associated with improvement of the 5-year DRFS 
in the low-risk subgroup (HR 1.652, 95% CI 0.805–3.390; P = 
0.171; Fig. 6b). 4. Discussion 
In our present study, we developed and validated a novel prognostic 
model based on 10 BCSC-associated miRNAs to improve the prediction 
of disease recurrence in patients with non-metastatic HR+HER2 − 
breast cancer. The prognostic value of this proposed classiﬁer is better 
than the well-established ICH4 scoring, 21-gene RS and other clinico­
pathological risk factors. As shown in our retrospective analysis, while 
patients in the low risk group gained little beneﬁt from chemotherapy, 
patients with higher recurrent risk deﬁned by our classiﬁer seem to 
beneﬁt from chemotherapy. Therefore, the 10-miRNA classiﬁer may 
be useful to predict chemotherapy sensitivity, but this needs further 
prospective studies. The 10 miRNAs incorporated into our predictive model have been 
shown to regulate the biology of BCSCs and non-stem cell like breast 
cancer cells (non-BCSCs) by various target genes, suggesting these 
miRNAs play crucial roles during the development of tumor. Among 
them, reduction in miR-30 family maintains self-renewal and inhibits 
apoptosis of BCSCs by reliving their suppression to UBC9 (Yu et al., 
2010), AVEN and FOXD1 (Ouzounova et al., 2013), while higher 
microRNA-30c expression was signiﬁcantly associated with beneﬁt of  
tamoxifen treatment in advanced ER+ breast cancer. Increased expres­
sion of miR-125b is associated with chemotherapy resistance and me­
tastasis in breast cancers (Okuda et al., 2013) whereas increased miR­
7 suppresses brain metastasis of BCSCs by modulating KLF4 expression. 
These ﬁndings implied that the selected miRNAs in our classiﬁer may 
have biological importance. Although in our study we did not have di­
rect evidence to support that these miRNAs inﬂuenced the clinical out­
comes via their target genes, this has no direct impact on their 
usefulness as biomarker. 
The prognostic and predictive roles of miRNAs have been investigat­
ed in several studies. For example, a MAPK–microRNA signature has 
been shown to predict endocrine resistance and poor survival in ER-
positive breast cancers (Miller et al., 2015). Nonetheless, we are still 
lack of well validated miRNA signatures that are applicable in clinical 
practice for diagnosis, prognosis and personalized therapy in breast can­
cer. As distinct from previous miRNA prognostic models, the 10 BCSC-
associated miRNAs classiﬁer was set up on the basis of the aggressive 
cancer biology, and its prognostic value has been validated both 
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Proﬁling of multiple gene expression by qRT-PCR or microarray, 
such as 21-gene testing and 70-gene MammaPrint signature, has been 
used in clinical practice to provide prognostic information and help in 
clinical decision for breast cancer patients. These assays have been ap­
proved to be used in clinics for predicting recurrence risks for early-
stage ER-positive breast cancer patients in western countries (Paik et 
al., 2004, 2006; van't Veer et al., 2005, 2002). Similarly, PAM50 assay 
provides a risk prediction for distant recurrence in HR-positive post­
menopausal breast cancers (Wallden et al., 2015). It has been reported 
that IHC4 scoring based on ER, PR, HER2 and Ki67 status has similar pre­
dictive value as the 21-gene risk scoring for ER+ breast cancer patients, 
and IHC4 scoring has also been widely used in routine clinical practice 
(Gourgou-Bourgade et al., 2015). When compared with the IHC4 scor­
ing, our 10 BCSC-associated miRNA classiﬁer demonstrated better prog­
nostic value for DRFS in the HR-positive, HER2-negative breast cancer 
patients regardless of lymph node or menopausal status. Furthermore, 
we performed a comparison of the prognostic value of miRNA classiﬁer 
and 21-gene RS in HR+HER2− patients with negative LN status. Our 
retrospective data showed that the miRNAs-based classiﬁer seemed to 
outperform the 21-gene RS in predicting the DRFS in this cohort. Several 
lines of explanation may be responsible for the different prognostic 
values of these gene assays. Firstly, the prognostic information of the 
ﬁrst generation signatures stems almost exclusively from the degree 
of expression of proliferation-related genes in ER+ cancers (Reis-Filho 
and Pusztai, 2011). In contrast, our classiﬁer did not display statistically 
signiﬁcant associations with Ki67 expression two out of the four co­
horts, and the prognostic risk score was constantly accurate when the 
analysis was stratiﬁed by ki67 expression level and histological grade, 
suggesting our signature provides information more than proliferation. 
Secondly, meta-analyses have revealed that tumor size and lymph-node 
status provided prognostic information that is independent of that of­
fered by prognostic generation signature (Wirapati et al., 2008). Also, 
a model combining risk score with traditional anatomical pathological 
factors could be more prognostic than risk alone (Pusztai, 2011). In con­
trast, our proposed classiﬁer can predict the DRFS of patients with 
HR+HER2− breast cancer, independent of clinicopathological fea­
tures, although further prospective trials are needed to validate its prog­
nostic value. Thirdly, previous predictive models were largely founded 
on the basis of computer-based algorithm, the function of some of the 
selected genes is not clear, and additional efforts were needed to ex­
plore their biological functions after the models were built. Therefore, 
hypothesis-driven approaches are alternative strategies to develop 
prognostic signatures for clinical outcomes (Reis-Filho and Pusztai, 
2011), which had been demonstrated in ovarian cancer. In our study, 
combining biology-driven and empirical approaches, we have selected a score of critical BCSC-associated miRNAs based on literature 
reviewing, trained them in our studying population and developed a 
valid prognostic model for HR+HER2− breast cancers. This approach 
is less time-consuming and more economical, cost-effective than the 
traditional strategy. However, it should also be noted that the pre-selec­
tion process of biomarker candidates based on one biology-driven hy­
pothesis may have inevitable bias. In addition to cancer stem cell 
properties, many other biological behaviors, such as epithelial-mesen­
chymal transition (EMT), drug resistance and anoikis, may also contrib­
ute to cancer progression and patient survival. Hence, pre-selected 
biomarkers focusing on one biological process may not completely re­
ﬂect the whole picture. Taken together, our present ﬁndings suggest 
that developing prognostic gene models using the combination of biol­
ogy-driven and empirical approaches is feasible, efﬁcient and cost-
effective. 
Albeit the present study demonstrated a successful example in con­
structing a prognostic model for cancer prognosis using a biology-driv­
en approach, the limitations of our study should be addressed. Firstly, 
although our present study found that the 10 BCSC-associated miRNAs 
classiﬁer could provide prognostic information for HR+HER2− breast 
cancer and potentially outperformed the 21-gene RS and IHC4 score, 
our study is limited by its retrospective design. Prospective randomized 
clinical trial is needed to validate the prognostic value of our current 
miRNA model. Also, the prospective randomized clinical trials with larg­
er cohort for head-to-head comparison between current miRNA model 
and 21-gene RS are required in the future. Secondly, there are signiﬁ­
cant discrepancies in the epidemiological characteristics, diagnostic 
methods, biological features, and treatment strategies of breast cancer 
between Asian and western countries (Sivasubramaniam et al., 2015). 
Given these discrepancies, the clinical applicability of this miRNA classi­
ﬁer should be validated in breast cancer patients from western coun­
tries. Thirdly, since most patients in our study were diagnosed before 
2008, the types of endocrine therapy, treatment periods and combined 
therapies changed over time, and may not be optimal. Thus, the associ­
ation between the miRNA classiﬁer and chemotherapeutic beneﬁt need  
further evaluation. Fourthly, approximately 50% of all tumor recurrence 
occurs in the ER-positive breast cancer patients after 5 years, the prog­
nostic value of this classiﬁer for prediction of late-recurrence should 
be tested in a breast cancer population with a longer follow-up. Last 
but not the least, although our present study found that the beneﬁt 
from chemotherapy in the low-risk group is small, our study is limited 
by its retrospective design. This limitation also applies to the develop­
ment and validation of our prognostic signature as described above. 
Therefore, prospective randomized clinical trial is needed to further val­
idate the predictive value of our 10 BCSC-associated miRNA model for 
chemotherapeutic beneﬁts in HR-positive, HER2-negative breast cancer 
patients. 
209 C. Gong et al. / EBioMedicine 11 (2016) 199–209 In summary, our study demonstrated that the 10 BCSC-associated 
miRNA prognostic model can effectively distinguish HR-positive, 
HER2-negative breast cancer patients with low recurrence risk from 
those with high recurrence risk, regardless of lymph node or menopaus­
al status and age at diagnosis. Since our 10-miRNA-based classiﬁer can 
provide better prognostic value than the traditional clinicopathological 
predictors in HR+HER2− breast cancer patients, it may be helpful to 
effectively distinguish the low risk cases from the high risk ones 
among HR-positive, HER2-negative breast cancer patients. In this sce­
nario, clinicians may be able to recommend less aggressive therapy for 
low-risk individuals in directing personalized therapy. Therefore, this 
model may facilitate personalized clinical decision making for 
HR+HER2− breast cancer patients. 
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